Royalty Pharma plc (RPRX): Total Assets
$19.62B
As of 2025-12-31
$19.82B
As of 2026-06-30
+5.3%
3-year compound annual growth
+4.1%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $19.62B | +7.7% | 2026-02-11, Balance as of period end |
| 2024-12-31 | $18.22B | +11.2% | 2026-02-11, Balance as of period end |
| 2023-12-31 | $16.38B | -2.6% | 2025-02-12, Balance as of period end |
| 2022-12-31 | $16.81B | -4.0% | 2024-02-15, Balance as of period end |
| 2021-12-31 | $17.52B | +9.3% | 2023-02-15, Balance as of period end |
| 2020-12-31 | $16.02B | +28.7% | 2022-02-15, Balance as of period end |
| 2019-12-31 | $12.45B | n/a | 2021-02-24, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Royalty Pharma plc (RPRX) | 2025-12-31 | $19.62B | +7.7% |
| Sarepta Therapeutics, Inc. (SRPT) | 2025-12-31 | $3.35B | -15.5% |
| Amneal Pharmaceuticals, Inc. (AMRX) | 2025-12-31 | $3.68B | +5.1% |
| United Therapeutics Corp (UTHR) | 2025-12-31 | $7.88B | +7.0% |
| BioMarin Pharmaceutical Inc (BMRN) | 2025-12-31 | $7.59B | +8.7% |
| PTC Therapeutics, Inc. (PTCT) | 2025-12-31 | $2.90B | +70.0% |
| Alnylam Pharmaceuticals, Inc. (ALNY) | 2025-12-31 | $4.97B | +17.1% |
| Phibro Animal Health Corp (PAHC) | 2026-06-30 | $1.50B | +10.3% |
| Alkermes plc. (ALKS) | 2025-12-31 | $2.49B | +21.0% |
Compare RPRX, SRPT, AMRX, UTHR side by side · Screen every company in Pharmaceutical Preparations ↗